Global Blood Therapeutics, Inc. (GBT)

Last Price:  

Company Description

Global Blood Therapeutics, Inc. is a biopharmaceutical company which is engaged in discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. Its product candidate consists of GBT440 is an oral, once-daily prophylactic therapy for sickle cell disease which is in clinical trial. The company in addition to GBT is involved in research and development activities targeted hypoxemic pulmonary disorders, including idiopathic pulmonary fibrosis and hereditary angioedema. Global Blood Therapeutics, Inc. is based in South San Francisco, California.

Financials, Fundamental Metrics & Ratios
Revenue (Most Recent Fiscal Year) $2.11M
Net Income (Most Recent Fiscal Year) $-266.77M
PE Ratio (Current Year Earnings Estimate) --
PE Ratio (Trailing 12 Months) --
PEG Ratio (Long Term Growth Estimate) --
Price to Sales Ratio (Trailing 12 Months) --
Price to Book Ratio (Most Recent Quarterly Book Value per Share) 8.21
Price to Cash Ratio (Most Recent Annual Cash Flow per Share) --
Pre-Tax Margin (Trailing 12 Months) -1792.61%
Net Margin (Trailing 12 Months) --
Return on Equity (Trailing 12 Months) -48.56%
Return on Assets (Trailing 12 Months) -39.45%
Current Ratio (Most Recent Fiscal Quarter) 9.07
Quick Ratio (Most Recent Fiscal Quarter) 8.83
Debt to Common Equity (Most Recent Fiscal Quarter) 0.30
Inventory Turnover (Trailing 12 Months) 0.05
Book Value per Share (Most Recent Fiscal Quarter) $9.61
Earnings per Share (Most Recent Fiscal Quarter) $-1.20
Earnings per Share (Most Recent Fiscal Year) $-4.71
Diluted Earnings per Share (Trailing 12 Months) $-4.87
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Common Shares Outstanding 60.94M
Free Float 58.38M
Market Capitalization $4.30B
Average Volume (Last 20 Days) 1.10M
Beta (Past 60 Months) 1.89
Percentage Held By Insiders (Latest Annual Proxy Report) 4.20%
Percentage Held By Institutions (Latest 13F Reports) --
Annual Dividend (Based on Last Quarter) $0.00
Dividend Yield (Based on Last Quarter) 0.00%